Literature DB >> 22285942

3D-QSAR and 3D-QSSR models of negative allosteric modulators facilitate the design of a novel selective antagonist of human α4β2 neuronal nicotinic acetylcholine receptors.

Brandon J Henderson1, Crina M Orac, Iwona Maciagiewicz, Stephen C Bergmeier, Dennis B McKay.   

Abstract

Subtype selective molecules for α4β2 neuronal nicotinic acetylcholine receptors (nAChRs) have been sought as novel therapeutics for nicotine cessation. α4β2 nAChRs have been shown to be involved in mediating the addictive properties of nicotine while other subtypes (i.e., α3β4 and α7) are believed to mediate the undesired effects of potential CNS drugs. To obtain selective molecules, it is important to understand the physiochemical features of ligands that affect selectivity and potency on nAChR subtypes. Here we present novel QSAR/QSSR models for negative allosteric modulators of human α4β2 nAChRs and human α3β4 nAChRs. These models support previous homology model and site-directed mutagenesis studies that suggest a novel mechanism of antagonism. Additionally, information from the models presented in this work was used to synthesize novel molecules; which subsequently led to the discovery of a new selective antagonist of human α4β2 nAChRs.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22285942      PMCID: PMC3274641          DOI: 10.1016/j.bmcl.2011.11.051

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  24 in total

Review 1.  Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations.

Authors:  Anders A Jensen; Bente Frølund; Tommy Liljefors; Povl Krogsgaard-Larsen
Journal:  J Med Chem       Date:  2005-07-28       Impact factor: 7.446

Review 2.  Brain nicotinic acetylcholine receptors: native subtypes and their relevance.

Authors:  Cecilia Gotti; Michele Zoli; Francesco Clementi
Journal:  Trends Pharmacol Sci       Date:  2006-07-31       Impact factor: 14.819

3.  Negative allosteric modulation of nicotinic acetylcholine receptors blocks nicotine self-administration in rats.

Authors:  Ryan F Yoshimura; Derk J Hogenkamp; Wen Y Li; Minhtam B Tran; James D Belluzzi; Edward R Whittemore; Frances M Leslie; Kelvin W Gee
Journal:  J Pharmacol Exp Ther       Date:  2007-09-14       Impact factor: 4.030

4.  Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors.

Authors:  Karla B Mihalak; F Ivy Carroll; Charles W Luetje
Journal:  Mol Pharmacol       Date:  2006-06-09       Impact factor: 4.436

5.  Nicotine activation of alpha4* receptors: sufficient for reward, tolerance, and sensitization.

Authors:  Andrew R Tapper; Sheri L McKinney; Raad Nashmi; Johannes Schwarz; Purnima Deshpande; Cesar Labarca; Paul Whiteaker; Michael J Marks; Allan C Collins; Henry A Lester
Journal:  Science       Date:  2004-11-05       Impact factor: 47.728

6.  Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid.

Authors:  H Rollema; L K Chambers; J W Coe; J Glowa; R S Hurst; L A Lebel; Y Lu; R S Mansbach; R J Mather; C C Rovetti; S B Sands; E Schaeffer; D W Schulz; F D Tingley; K E Williams
Journal:  Neuropharmacology       Date:  2006-12-08       Impact factor: 5.250

7.  Ring E analogs of methyllycaconitine (MLA) as novel nicotinic antagonists.

Authors:  S C Bergmeier; D J Lapinsky; R B Free; D B McKay
Journal:  Bioorg Med Chem Lett       Date:  1999-08-02       Impact factor: 2.823

8.  Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone.

Authors:  J E Rose; F M Behm; E C Westman; E D Levin; R M Stein; G V Ripka
Journal:  Clin Pharmacol Ther       Date:  1994-07       Impact factor: 6.875

9.  Quantitative structure-selectivity relationship for M2 selectivity between M1 and M2 of piperidinyl piperidine derivatives as muscarinic antagonists.

Authors:  Yin-Yao Niu; Li-Min Yang; Ke-Min Deng; Jian-Hua Yao; Liang Zhu; Cong-Ying Chen; Min Zhang; Jin-E Zhou; Tian-Xiang Shen; Hong-Zhuan Chen; Yang Lu
Journal:  Bioorg Med Chem Lett       Date:  2007-01-25       Impact factor: 2.823

10.  Structure activity studies of ring E analogues of methyllycaconitine. Part 2: Synthesis of antagonists to the alpha3beta4* nicotinic acetylcholine receptors through modifications to the ester.

Authors:  Stephen C Bergmeier; Khadiga A Ismail; Kristjan M Arason; Susan McKay; Darrell L Bryant; Dennis B McKay
Journal:  Bioorg Med Chem Lett       Date:  2004-07-16       Impact factor: 2.823

View more
  3 in total

1.  Defining the putative inhibitory site for a selective negative allosteric modulator of human α4β2 neuronal nicotinic receptors.

Authors:  Brandon J Henderson; Tatiana F González-Cestari; Bitna Yi; Ryan E Pavlovicz; R Thomas Boyd; Chenglong Li; Stephen C Bergmeier; Dennis B McKay
Journal:  ACS Chem Neurosci       Date:  2012-05-25       Impact factor: 4.418

2.  Discovery of benzamide analogs as negative allosteric modulators of human neuronal nicotinic receptors: pharmacophore modeling and structure-activity relationship studies.

Authors:  Bitna Yi; Sihui Long; Tatiana F González-Cestari; Brandon J Henderson; Ryan E Pavlovicz; Karl Werbovetz; Chenglong Li; Dennis B McKay
Journal:  Bioorg Med Chem       Date:  2013-04-06       Impact factor: 3.641

3.  Allosteric transition: a comparison of two models.

Authors:  Niels Bindslev
Journal:  BMC Pharmacol Toxicol       Date:  2013-01-08       Impact factor: 2.483

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.